Littérature scientifique sur le sujet « Beltona Records »

Triassic lungfish (Dipnoi) have been extensively documented from the Gondwanan continental and marine shelf deposits of Africa and Madagascar (Teixeira, 1949; Lehman et al., 1959; Beltan, 1968; Martin, 1979, 1981; Kemp 1996), Australia (Kemp, 1993, 1994, 1997a, 1998), India (Jain et al, 1964; Jain, 1968), and Antarctica (Dziewa, 1980). Numerous records also exist from Laurasian landmasses including Europe (Agassiz, 1838; Schultze, 1981), North America (Case, 1921) and central and eastern Asia (Liu and Yeh, 1957; Vorobyeva, 1967; Martin and Ingavat, 1982). By comparison, nothing is known of contemporary lungfish fossils from the Middle East. Thus, the recent recovery of a single tooth plate representing a new geographic occurrence of the genus Ceratodus Agassiz, 1838 from paralic marine deposits of the Jilh Formation, a latest Anisian to lower Carnian unit that crops out along the eastern margin of the Proterozoic Arabian Shield in central Saudi Arabia (Fig. 1), is significant because it provides the stratigraphically oldest record of dipnoans from the Arabian Peninsula.

Penelitian ini bertujuan untuk mengetahui berapa kerugian mesin yang mengalami kerusakan dan mengurangi down time yang sangat tinggi dengan menerapkan strategi perbaikan keandalan pada mesin Corrugator type H-200 dengan metode Reliability Centered Maintenance (RCM) dan Overall Measure of Maintenance Performance (OMMP) yaitu penentuan perencanaan perawatan yang tepat agar bisa cepat terselesaikan. Penelitian ini dilakukan untuk menghasilkan desain perawatan perbaikan yang tepat sasaran dan terencana. Hasil penelitian menunjukan bahwa kerugian diketahui dari data down time bulan mei sebesar Rp. 500.000/ jam pada saat komponen mesin paling banyak mengalami kerusakan, pada diagram pareto efek kerusakan tertinggi pertama pada bearing spleser dengan frekuensi kumulatif 10% serta yang kedua pada rantai- belting conveyor yang penuh kotoran dengan frekuensi kumulatif 19%, dan untuk analisis strategi perbaikan dengan yaitu dengan pemberian alat bantu pipa besi elastis untuk penyaluran grease pada bearing roll spleser serta memabahkan alat tambahan pipa besi untuk membersihkan rantai-belting conveyor yang penuh kotoran pada bagian atas mesin C-Flute dan B-Flute, untuk penjadwalan perawatan terencana dilakukan 3 bulan sekali dengan mengacu data records lembar check sheet.

Abstract The article presents a study of the electro-mechanical loading of the motor-reducer group for driving a belt conveyor. The current of the two drive motors has been measured following an emergency replacement of the reducer gear and the hydraulic clutch of the first drive unit. The traction forces in the belting generated by the two driving drums have been established. A comparison is made of the current records from this study and those from the enterprise information system. Thermal imaging photos have been taken of the two reducers and the hydraulic clutches of the drive units. The electromechanical state of the motor-reducer groups is analyzed and conclusions are drawn regarding the operation of the belt conveyor.

Abstract. Dams and their reservoirs generate major impacts on society and the environment. In general, its relevance relies on facilitating the management of water resources for anthropogenic purposes. However, dams could also generate many potential adverse impacts related to safety, ecology or biodiversity. These factors, as well as the additional effects that climate change could cause in these infrastructures and their surrounding environment, highlight the importance of dams and the necessity for their continuous monitoring and study. There are several studies examining dams both at regional and global scales; however, those that include the South America region focus mainly on the most renowned basins (primarily the Amazon basin), most likely due to the lack of records on the rest of the basins of the region. For this reason, a consistent database of georeferenced dams located in South America is presented: Dataset of Georeferenced Dams in South America (DDSA). It contains 1010 entries of dams with a combined reservoir volume of 1017 km3, and it is presented in the form of a list describing a total of 24 attributes that include the dams' names, characteristics, purposes and georeferenced locations. Also, hydrological information on the dams' catchments is also included: catchment area, mean precipitation, mean near-surface temperature, mean potential evapotranspiration, mean runoff, catchment population, catchment equipped area for irrigation, aridity index, residence time and degree of regulation. Information was obtained from public records, governments records, existing international databases and extensive internet research. Each register was validated individually and geolocated using public-access online map browsers, and then, hydrological and additional information was derived from a hydrological model computed using the HydroSHEDS (Hydrological data and maps based on SHuttle Elevation Derivatives at multiple Scales) dataset. With this database, we expect to contribute to the development of new research in this region. The database is publicly available at https://doi.org/10.5281/zenodo.4315647 (Paredes-Beltran et al., 2020).

Plant has many benefit in life, one of example is etnic’s edible food. Jerieng etnic is origin etnic living in the west Bangka district, Bangka Beltung province. Food is everything that grows, lives, has stem, roots, and leaves are eaten directly or need to be processed. The purpose of this research is to record the diversity of food crops (types of edible plant based food, number of species, parts used, processing. This research was conducted from January to November 2018. The research in 13 villages in Simpang Teritip District, West Bangka Regency. Locations include Pelangas Village, Simpang Gong, Air Nyatoh, Pangek, Peradong, Kundi, Air Menduyung, Rambat, Simpang Tiga, Terak Hill, Ibul, Berang, and Mayang. This research aims to do interview and direct observation with the key informant using purposive sampling method. The result of this research found that there are 79 species from 34 families of edible plant-based food in Jerieng etnic. Solanaceae is the most numerous family found including 9 species. The most often used plant part is fruit (39%), meanwhile the less often used plant part is bud (1%). Edible plant based food by Jerieng etnic is divided into two groups, those are processed food and unprocessed food. Example of unprocessed food is local salad (known as “lalapan”) and the processed food such as lempah darat and lempah kuning.

Abstract Background: Although there is increased awareness leading to early detection and prevention, Hispanic American (HA) men with prostate cancer (PC) continue to have greater mortality rates compared to their Non-Hispanic White (NHW) counterparts. Moreover, HA men with PC are more likely to have more advanced disease compared to NHW men. Here, we characterized the molecular and immune differences in HA and NHW tumors and their association with PC ethnic disparity. Methods: 88 PC samples (HA=34, NHW=54) obtained from treatment-naive metastatic hormone-sensitive PC (mHSPC) were analyzed by next-generation sequencing (592, NextSeq; WES, NovaSeq), Whole Transcriptome Sequencing (WTS; NovaSeq) (Caris Life Sciences, Phoenix, AZ). AR signature and NEPC score were calculated based on the expression level of previously defined genes (Hieronymus et al. 2006, Beltran et al. 2016). Medical record was reviewed in a deidentified fashion for clinal features. Statistical significance was determined using chi-square and Mann-Whitney U (p<0.05). Results: HA patients with PC had higher level of PSA (111.5 vs 52.6 ng/ml, p=0.12) and stage (T4: 41% vs 14% p=0.01, M1c: 41% vs 16% p=0.04) but no significant difference in frequency of Gleason score > 4 (79% vs 73%, p=0.61) or stage N1 (69% vs 61%, p=0.85) compared to NHW. HA PC had a significantly higher frequency of TMPRSS2-fusion (46.4% vs 20.0%, p=0.04) compared to NHW PC. By Gene Set Enrichment Analysis, HA PC had enrichment of KRAS signaling (NES: 1.44, FDR=0.02), Hedgehog signaling (NES: 1.45, FDR=0.04), NOTCH signaling (NES: 1.41, FDR=0.07), Hypoxia (NES: 1.38, FDR=0.10) and IL2-STAT5 signaling (NES: 1.35, FDR=0.10) pathways compared to NHW tumors. There was no difference in median Androgen Receptor signature (p=0.78) or Neuroendocrine Prostate Cancer (NEPC) score (p=0.79). Also, no significant difference in AR positivity by IHC (100% vs 95.7%) between HA and NHW PC tumors (p=0.51). HA PC had significantly higher expression of stem cell markers ALDH1A1 (2.1-fold), ALDH1A2 (3-fold), and PROM1 (1.6-fold) and immunoinhibitory genes PDCD1LG2 (1.68-fold) and FOXP3 (1.45-fold) compared to NHW tumors (all p<0.05). Additionally, HA tumors had increased infiltration of M1 Macrophages (0.72% vs 0%) and NK cells (4.84% vs 3.55%, all p<0.05), and increased T-cell inflamed score (44.0 vs -49.0, p=0.14) compared to NHW. Conclusion: Our data suggest that HA mHSPC is associated with higher levels of PSA, stage, TMPRSS2-fusions, stemness marker expression, immunoinhibitory gene expression, and increased M1 Macrophage and NK cell infiltration. Together, these findings suggest a crucial role of differential molecular and tumor immune microenvironment in PC ethnic disparity. A better understanding of these differences with additional research may help in designing the approaches for reducing the ethnic disparities gaps in PC patients. Citation Format: Alejandro Recio-Boiles, Sachin Kumar Deshmukh, Juan Chipollini, Ken Batai, Sharon Wu, Joanne Xiu, Alex Farrell, Milan Radovich, Elisabeth Heath, Rana McKay, Chadi Nabhan. Molecular characterization of prostate cancer between Hispanic American and Non-Hispanic Whites: Implications for cancer ethnic health disparities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1895.

OBJECTIVES/GOALS: Characterize formal informatics methods and approaches for enabling reproducible translational research. Education of reproducible methods to translational researchers and informaticians. METHODS/STUDY POPULATION: We performed a scoping review [1] of selected informatics literature (e.g. [2,3]) from PubMed and Scopus. In addition we reviewed literature and documentation of translational research informatics projects [4–21] at the University of Utah. RESULTS/ANTICIPATED RESULTS: The example informatics projects we identified in our literature covered a broad spectrum of translational research. These include research recruitment, research data requisition, study design and statistical analysis, biomedical vocabularies and metadata for data integration, data provenance and quality, and uncertainty. Elements impacting reproducibility of research include (1) Research Data: its semantics, quality, metadata and provenance; and (2) Research Processes: study conduct including activities and interventions undertaken, collections of biospecimens and data, and data integration. The informatics methods and approaches we identified as enablers of reproducibility include the use of templates, management of workflows and processes, scalable methods for managing data, metadata and semantics, appropriate software architectures and containerization, convergence methods and uncertainty quantification. In addition these methods need to be open and shareable and should be quantifiable to measure their ability to achieve reproducibility. DISCUSSION/SIGNIFICANCE OF IMPACT: The ability to collect large volumes of data collection has ballooned in nearly every area of science, while the ability to capturing research processes hasn’t kept with this pace. Potential for problematic research practices and irreproducible results are concerns.Reproducibility is a core essentially of translational research. Translational research informatics provides methods and means for enabling reproducibility and FAIRness [22] in translational research. In addition there is a need for translational informatics itself to be reproducible to make research reproducible so that methods developed for one study or biomedical domain can be applied elsewhere. Such informatics research and development requires a mindset for meta-research [23].The informatics methods we identified covers the spectrum of reproducibility (computational, empirical and statistical) and across different levels of reproducibility (reviewable, replicable, confirmable, auditable, and open or complete) [24–29]. While there are existing and ongoing efforts in developing informatics methods for translational research reproducibility in Utah and elsewhere, there is a need to further develop formal informatics methods and approaches: the Informatics of Research Reproducibility.In this presentation, we summarize the studies and literature we identified and discuss our key findings and gaps in informatics methods for research reproducibility. We conclude by discussing how we are covering these topics in a translational research informatics course.1.Pham MT, Rajić A, Greig JD, Sargeant JM, Papadopoulos A, McEwen SA. A scoping review of scoping reviews: advancing the approach and enhancing the consistency. Res Synth Methods. 2014 Dec;5(4):371–85.2.McIntosh LD, Juehne A, Vitale CRH, Liu X, Alcoser R, Lukas JC, Evanoff B. Repeat: a framework to assess empirical reproducibility in biomedical research. BMC Med Res Methodol [Internet]. 2017 Sep 18 [cited 2018 Nov 30];17. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604503/3.Denaxas S, Direk K, Gonzalez-Izquierdo A, Pikoula M, Cakiroglu A, Moore J, Hemingway H, Smeeth L. Methods for enhancing the reproducibility of biomedical research findings using electronic health records. BioData Min. 2017;10:31.4.Burnett N, Gouripeddi R, Wen J, Mo P, Madsen R, Butcher R, Sward K, Facelli JC. Harmonization of Sensor Metadata and Measurements to Support Exposomic Research. In: 2016 International Society of Exposure Science [Internet]. Research Triangle Park, NC, USA; 2017 [cited 2017 Jun 17]. Available from: http://www.intlexposurescience.org/ISES20175.Butcher R, Gouripeddi RK, Madsen R, Mo P, LaSalle B. CCTS Biomedical Informatics Core Research Data Service. In Salt Lake City; 2016.6.Cummins M, Gouripeddi R, Facelli J. A low-cost, low-barrier clinical trials registry to support effective recruitment. In Salt Lake City, Utah, USA; 2016 [cited 2018 Nov 30]. Available from: //campusguides.lib.utah.edu/UtahRR16/abstracts7.Gouripeddi R, Warner P, Madsen R, Mo P, Burnett N, Wen J, Lund A, Butcher R, Cummins MR, Facelli J, Sward K. An Infrastructure for Reproducibile Exposomic Research. In: Research Reproducibility 2016 [Internet]. Salt Lake City, Utah, USA; 2016 [cited 2018 Nov 30]. Available from: //campusguides.lib.utah.edu/UtahRR16/abstracts8.Eilbeck K, Lewis SE, Mungall CJ, Yandell M, Stein L, Durbin R, Ashburner M. The Sequence Ontology: a tool for the unification of genome annotations. Genome Biol. 2005;6:R44.9.Gouripeddi R, Cummins M, Madsen R, LaSalle B, Redd AM, Presson AP, Ye X, Facelli JC, Green T, Harper S. Streamlining study design and statistical analysis for quality improvement and research reproducibility. J Clin Transl Sci. 2017 Sep;1(S1):18–9.10.Gouripeddi R, Eilbeck K, Cummins M, Sward K, LaSalle B, Peterson K, Madsen R, Warner P, Dere W, Facelli JC. A Conceptual Architecture for Reproducible On-demand Data Integration for Complex Diseases. In: Research Reproducibility 2016 (UtahRR16) [Internet]. Salt Lake City, Utah, USA; 2016 [cited 2017 Apr 25]. Available from: https://zenodo.org/record/16806711.Gouripeddi R, Lane E, Madsen R, Butcher R, LaSalle B, Sward K, Fritz J, Facelli JC, Cummins M, Shao J, Singleton R. Towards a scalable informatics platform for enhancing accrual into clinical research studies. J Clin Transl Sci. 2017 Sep;1(S1):20–20.12.Gouripeddi R, Deka R, Reese T, Butcher R, Martin B, Talbert J, LaSalle B, Facelli J, Brixner D. Reproducibility of Electronic Health Record Research Data Requests. In Washington, DC, USA; 2018 [cited 2018 Apr 21]. Available from: https://zenodo.org/record/1226602#.WtvvyZch27013.Gouripeddi R, Mo P, Madsen R, Warner P, Butcher R, Wen J, Shao J, Burnett N, Rajan NS, LaSalle B, Facelli JC. A Framework for Metadata Management and Automated Discovery for Heterogeneous Data Integration. In: 2016 BD2K All Hands Meeting [Internet]. Bethesda, MD; November 29-30 [cited 2017 Apr 25]. Available from: https://zenodo.org/record/16788514.Groat D, Gouripeddi R, Lin YK, Dere W, Murray M, Madsen R, Gestaland P, Facelli J. Identification of High-Level Formalisms that Support Translational Research Reproducibility. In: Research Reproducibility 2018 [Internet]. Salt Lake City, Utah, USA; 2018 [cited 2018 Oct 30]. Available from: //campusguides.lib.utah.edu/UtahRR18/abstracts15.Huser V, Kahn MG, Brown JS, Gouripeddi R. Methods for examining data quality in healthcare integrated data repositories. Pac Symp Biocomput Pac Symp Biocomput. 2018;23:628–33.16.Lund A, Gouripeddi R, Burnett N, Tran L-T, Mo P, Madsen R, Cummins M, Sward K, Facelli J. Enabling Reproducible Computational Modeling: The Utah PRISMS Ecosystem. In Salt Lake City, Utah, USA; 2018 [cited 2018 Oct 30]. Available from: //campusguides.lib.utah.edu/UtahRR18/abstracts17.Pflieger LT, Mason CC, Facelli JC. Uncertainty quantification in breast cancer risk prediction models using self-reported family health history. J Clin Transl Sci. 2017 Feb;1(1):53–9.18.Shao J, Gouripeddi R, Facelli J. Improving Clinical Trial Research Reproducibility using Reproducible Informatics Methods. In Salt Lake City, Utah, USA; 2018 [cited 2018 Oct 30]. Available from: //campusguides.lib.utah.edu/UtahRR18/abstracts19.Shao J, Gouripeddi R, Facelli JC. Semantic characterization of clinical trial descriptions from ClincalTrials.gov and patient notes from MIMIC-III. J Clin Transl Sci. 2017 Sep;1(S1):12–12.20.Tiase V, Gouripeddi R, Burnett N, Butcher R, Mo P, Cummins M, Sward K. Advancing Study Metadata Models to Support an Exposomic Informatics Infrastructure. In Ottawa, Canada; 2018 [cited 2018 Oct 30]. Available from: = http://www.eiseverywhere.com/ehome/294696/638649/?&t=8c531cecd4bb0a5efc6a0045f5bec0c321.Wen J, Gouripeddi R, Facelli JC. Metadata Discovery of Heterogeneous Biomedical Datasets Using Token-Based Features. In: IT Convergence and Security 2017 [Internet]. Springer, Singapore; 2017 [cited 2017 Sep 6]. p. 60–7. (Lecture Notes in Electrical Engineering). Available from: https://link.springer.com/chapter/10.1007/978-981-10-6451-7_822.Wilkinson MD, Dumontier M, Aalbersberg IjJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten J-W, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJG, Groth P, Goble C, Grethe JS, Heringa J, ’t Hoen PAC, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone S-A, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016 Mar 15;3:160018.23.Ioannidis JPA. Meta-research: Why research on research matters. PLOS Biol. 2018 Mar 13;16(3):e2005468.24.Stodden V, Borwein J, Bailey DH. Setting the default to reproducible. Comput Sci Res SIAM News. 2013;46(5):4–6.25.Stodden V, McNutt M, Bailey DH, Deelman E, Gil Y, Hanson B, Heroux MA, Ioannidis JPA, Taufer M. Enhancing reproducibility for computational methods. Science. 2016 Dec 9;354(6317):1240–1.26.Stodden V, McNutt M, Bailey DH, Deelman E, Gil Y, Hanson B, Heroux MA, Ioannidis JPA, Taufer M. Enhancing reproducibility for computational methods. Science. 2016 Dec 9;354(6317):1240–1.27.Stodden V. Reproducible Research for Scientific Computing: Tools and Strategies for Changing the Culture. Comput Sci Eng. 2012 Jul 1;14(4):13–7.28.Baker M. Muddled meanings hamper efforts to fix reproducibility crisis. Nat News Available from: http://www.nature.com/news/muddled-meanings-hamper-efforts-to-fix-reproducibility-crisis-1.2007629.Barba LA. Terminologies for Reproducible Research. ArXiv180203311 Cs 2018 Feb 9; Available from: http://arxiv.org/abs/1802.03311

Abstract Background: Advances in prevention, early detection, and treatment have resulted in a 29% reduction in cancer mortality since 1990 and unprecedented increases in the number of cancer survivors. There are more than 16.9M survivors living in the US today and 22.1M are expected by 2030. Cancer survivorship outcomes vary by race/ethnicity, socioeconomic status (SES), and more. Cancer is the leading cause of deaths in Hispanics/Latinos (H/Ls), a critical issue given that H/Ls are the largest ethnic minority group in the US and will account for 30% of the US population by 2060. H/Ls are disproportionately impacted by cancer due to inequities in SES and healthcare access, which leads to differences in risk factors/exposures and barriers to high-quality cancer prevention, early detection, and treatment. Although H/Ls have lower incidence rates for most common cancer types, significant disparities exist in prevalence, invasiveness, and mortality in specific cancers and across multiple patient-reported outcomes, such as quality of life and symptom burden. However, there is limited work documenting survivorship experiences among H/Ls. Purpose: The Avanzando Caminos multisite cohort study was established to address critical gaps in the science of H/L survivorship. It aims to examine the influence of sociocultural, medical, stress, psychosocial, lifestyle, behavioral, and biological factors on symptom burden, health-related quality of life, and clinical outcomes among H/Ls who have been previously treated for cancer. Methods: Avanzando Caminos, a collaboration between the Sylvester Comprehensive Cancer Center at the University of Miami and the Mays Cancer Center at UT Health San Antonio, is a 6-year prospective, cohort-based study of 3,000 H/Ls (1,500 in South Florida and 1,500 in South Texas) who completed primary cancer treatment within the past five years for stomach, liver, cervical, colorectal, lung, breast, kidney, or prostate cancers. Participants will complete self-report measures at baseline, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years. Blood draws to assess leukocyte gene expression, cardiometabolic markers, and genetic admixture will be collected at baseline, 1 year, 3 years, and 5 years. Medical and cancer characteristics and clinical outcomes will be extracted from the electronic medical record and/or state cancer registry at each time point. Data analysis will include general latent variable modeling with maximum likelihood robust variance estimation. Results: So far, we have recruited 398 H/L participants with a mean age of 59.49 years, 62% are female, 35% are Mexican, 57% Cuban, 24% Central/South American, 78% Puerto Rican, and 7% other. Preliminary results will include sociocultural, quality of life, stress, and other factors impacting H/Ls survivors. Conclusions: Avanzando Caminos is expected to fill critical gaps in knowledge to guide future secondary and tertiary prevention efforts to mitigate cancer disparities and optimize health-related quality of life among Hispanic/Latino cancer survivors. Citation Format: Amelie G. Ramirez, Patricia Chalela, Stephanie Rowan, Ysabel R. Lew, Victoria C. Garza, Natalie Rodriguez, Myriam N. Gonzalez, Britney E. Ortiz, Dorothy Long Parma, Edgar Muñoz, Yidong Chen, Chen-Pin Wang, Adolfo E. Diaz Duque, Luz M. Garcini, Dolores M. Perdomo, Stefanie V. Beltran, Gabrielle Montes de Oca, Maria Baraya, Akina Natori, Madeline H. Krause, Paulo S. Pinheiro, Patricia I. Moreno, Michael H. Antoni, Carmen Calfa, Olveen Carrasquillo, Gilberto Lopes, Steve Cole, Frank J. Penedo. Avanzando Caminos (Leading Pathways): The Hispanic/Latino cancer survivorship cohort study [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr B044.

BackgroundInterstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated efficacy in RA-ILD[1-2].Clinical trials have shown equivalence in subcutaneous (SC) and intravenous (IV) administration of ABA for articular manifestations[3].However, it has not been studied in RA-ILD.Objectivesto compare the effectiveness of ABA in RA-ILD patients according to the route of administration (IV-ABA vs SC-ABA).MethodsNational multicenter study of RA-ILD patients on treatment with ABA. They were divided into 2 groups according to the route of administration: a) IV, and b) SC. We analyzed from baseline the following outcomes in both groups:a) forced vital capacity (FVC),b) diffusing capacity of the lungs for carbon monoxide (DLCO),c) chest high resolution computed tomography (HRCT),d) dyspnea (assessed with the modified Medical Research Council scale),e) arthritis activity (assessed with DAS28-ESR or described in clinical records), andf) sparing corticosteroids effect.ResultsWe studied a total of 392 [SC-ABA/IV-AB; 288/91(available data)] patients. Baseline demographic and clinical characteristics are shown inTable 1. Patients were followed-up for a median [IQR] of 24 [10-48] months. FVC and DLCO remain stable during the first 24 months in both SC-ABA and IV-ABA[Figure 1].Dyspnea stabilized or improved in 85% of patients (89% of IV-ABA; 83% of SC-ABA). ABA was withdrawn in 80 patients: 60 (39%) in SC-ABA group and 20 (22%) in IV-ABA group. ILD worsening and articular inefficacy were the most common reasons of ABA discontinuation.ConclusionIn RA-ILD, ABA seems equally effective and safe regardless of the route of administration IV or SC.References[1] Rheumatology (Oxford). 2020 Dec 1;59(12):3906-3916.[2] Rheumatology (Oxford). 2021 Dec 24;61(1):299-308.[3] Arthritis Rheum. 2011 Oct;63(10):2854-64.Table 1.Main general features at baseline of RA-ILD patients with subcutaneous vs intravenous ABA.All ABA (n=392)ABA IV (n=91)ABA SC (n=288)pAge, years mean±SD65 ± 1066 ± 1066 ± 100.85Women n (%)226 (58)54 (59)166 (58)0.77Smoker ever n (%)210 (54)49 (54)154 (53)0.95ILD duration up to ABA, months, median [IQR]11 (3-38)11 (2-48)10 (3-36)0.65RF n (%)347 (89)78 (86)256 (89)0.41ACPA n (%)344 (89)76 (85)256 (90)0.25DAS28-ESR4.35±1.584.19±1.524.38±1.530.35ILD pattern n (%) NIU172 (44)47 (52)122 (42) NINE117 (30)20 (22)94 (33)0.14 Other98 (25)23 (26)72 (25)FVC (% of the predicted) mean±SD87 ± 2182 ± 2288 ± 210.26DLCO (% of the predicted) mean±SD67 ± 2067 ± 2067 ± 190.97Prednisone at baseline, mg/day, median [IQR]5 (5-10)7.5 (5-10)5 (5-10)0.34ACPA, anti-citrullinated protein antibodies; DLCO, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; RF, rheumatoid factor; UIP, usual interstitial pneumonia.Figure 1.Evolution of pulmonary function tests (mean % of the predicted FVC and DLCO) in RA-ILD patients with SC-ABA vs IV-ABA therapy at baseline and 24 months.Members of the Spanish Collaborative Group of Abatacept in RA-ILD patients:Luis Arboleya-Rodríguez, Javier Narváez, Juan Carlos Fernández, Belén Miguel, Iván Cabezas, Andrea García Valle, Clara Aguilera Cros, S. Romero-Yuste, Ignacio Villa Blanco, Sabela Fernández Aguado, Raquel Almodóvar, C. Ojeda-García, C. Aguilera-Cros, B. García-Magallón, Antonio Juan Mas, M. J. Moreno-Ramos, A. Ruibal-Escribano, Rosa Expósito, José Antonio Bernal, Evelin C. Cervantes, S. Rodríguez-García, R. Castellanos-Moreira, Iván Castellví, Manuel Rodríguez, Eva Salgado, Enrique Raya, Pilar Morales, Lorena Expósito, Mª Noelia Álvarez, José Luis Andreu, E. F. Vicente-Rabaneda, A. M. López-Robles, M. López-Corbeto, C. Hidalgo-Calleja, J.C. Fernández-López, Alejandro Olivé, S. Rodríguez-Muguruza, Iñigo Hernández, N. Quillis-Marti, J.A. Bernal-Vidal, A. García-Aparicio, S. Castro-Oreiro, J. Fernández-Melón, P. Vela Casasempere, María C. Fito, M. Rodríguez-Gómez, D. Palma-Sánchez, L. Expósito-Pérez, José María Andreu.Acknowledgements:NIL.Disclosure of InterestsAna Serrano-Combarro: None declared, Belén Atienza-Mateo: None declared, N. Del-Val: None declared, Libe Ibarrola Paino: None declared, Ivette Casafont-Solé: None declared, Rafael Melero: None declared, Alba Pérez Linaza: None declared, Isabel Serrano-García: None declared, Santos Castañeda: None declared, Rafaela Ortega Castro: None declared, Jerusalem Calvo Gutierrez: None declared, Natalia Mena-Vázquez: None declared, Nuria Vegas-Revenga: None declared, Lucía Domínguez Casas: None declared, C. Delgado-Beltran: None declared, Carolina Díez: None declared, Trinidad Pérez Sandoval: None declared, M. Retuerto-Guerrero: None declared, Lorena Pérez Albaladejo: None declared, R. López-Sánchez: None declared, Mª Guadalupe Mazano: None declared, Anahy Brandy-Garcia: None declared, Patricia López Viejo: None declared, Gemma Bonilla: None declared, Olga Maiz: None declared, Maria del Carmen Carrasco Cubero: None declared, Marta Garijo Bufort: None declared, Mireia Moreno: None declared, ANA URRUTICOECHEA-ARANA: None declared, Sergi Ordoñez: None declared, C. González-Montagut Gómez: None declared, C. Peralta-Ginés: None declared, Juan Ramón De Dios Jiménez de Aberásturi: None declared, Maria Camila Osorio: None declared, Elena Cañadillas: None declared, Fernando Lozano Morillo: None declared, Tomas Vazquez Rodriguez: None declared, Patricia Carreira: None declared, J M Blanco: None declared, Carlos Fernández-Díaz: None declared, J. Loricera: None declared, Iván Ferraz-Amaro: None declared, Diego Ferrer: None declared, Ricardo Blanco Speakers bureau: Abbvie, Pfizer, Roche, lilly, Bristol-Myers, Janssen, Galapagos and MSD, Consultant of: Abbvie, Pfizer, Roche, lilly, Bristol-Myers, Janssen and MSD, Grant/research support from: Abbvie, MSD, novartis and Roche.